Distinct lesion morphology at 7-T MRI differentiates neuromyelitis optica from multiple sclerosis

Objective: To investigate distinct white matter and cortical gray matter pathology in neuromyelitis optica spectrum disorders (NMOSDs) and multiple sclerosis (MS) at 7-T MRI in a cross-sectional study. Methods: We included 10 patients with NMOSDs and 18 patients with MS in our 7-T MRI study. The imaging protocol comprised T2*-weighted fast low angle shot and turbo inversion recovery magnitude sequences. White matter and cortical gray matter lesions were assessed with special regard to their (perivascular) localization as well as the expression of a hypointense rim. Results: In total, we detected 140 white matter lesions in 7 of 10 patients with NMOSDs. In contrast to MS plaques, which were nearly exclusively centered by a small vein (92%) and showed a characteristic hypointense rim (23%), white matter changes in patients with NMOSDs were nonspecific in appearance and were only infrequently neighbored by a blood vessel (49 lesions [35%], p = 0.003). Hypointense rims were very rarely detectable (3 lesions [2%], p < 0.001). Cortical pathology was absent in NMOSDs. In our MS cohort, we detected 36 leukocortical, 8 intracortical, and 8 subpial cortical lesions in 7 of 18 patients. Conclusion: The MRI features of white matter and the absence of cortical gray matter findings substantially differentiate NMOSDs from MS and can be used as a potential marker to distinguish these 2 entities. The fact that cortical pathology is common in MS but is not present in patients with NMOSDs may reflect the difference in the underlying pathogenesis.

[1]  C. Pfueller,et al.  Multiple sclerosis lesions and irreversible brain tissue damage: a comparative ultrahigh-field strength magnetic resonance imaging study. , 2012, Archives of neurology.

[2]  F. Paul,et al.  Failure of natalizumab to prevent relapses in neuromyelitis optica. , 2012, Archives of neurology.

[3]  F. Paul,et al.  Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients , 2012, Journal of Neuroinflammation.

[4]  Mike P. Wattjes,et al.  Lesion detection at seven Tesla in multiple sclerosis using magnetisation prepared 3D-FLAIR and 3D-DIR , 2011, European Radiology.

[5]  Y. Long,et al.  Comparative Brain Stem Lesions on MRI of Acute Disseminated Encephalomyelitis, Neuromyelitis Optica, and Multiple Sclerosis , 2011, PloS one.

[6]  P S Morgan,et al.  Ultra-high-field imaging distinguishes MS lesions from asymptomatic white matter lesions , 2011, Neurology.

[7]  Jeffrey A. Cohen,et al.  Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.

[8]  J. Parisi,et al.  Absence of cortical demyelination in neuromyelitis optica , 2010, Neurology.

[9]  B. Hemmer,et al.  Quantification and functional characterization of antibodies to native aquaporin 4 in neuromyelitis optica. , 2010, Archives of neurology.

[10]  Nikos Evangelou,et al.  3 Tesla and 7 Tesla MRI of multiple sclerosis cortical lesions , 2010, Journal of magnetic resonance imaging : JMRI.

[11]  S. Tsuji,et al.  IFNβ-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum , 2010, Neurology.

[12]  David Pitt,et al.  Imaging cortical lesions in multiple sclerosis with ultra-high-field magnetic resonance imaging. , 2010, Archives of neurology.

[13]  Brigitte Wildemann,et al.  AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance , 2010, Nature Reviews Neurology.

[14]  A. Lutterotti,et al.  Patterns of Antibody Binding to Aquaporin-4 Isoforms in Neuromyelitis Optica , 2010, PloS one.

[15]  K. Wandinger,et al.  Standardized method for the detection of antibodies to aquaporin-4 based on a highly sensitive immunofluorescence assay employing recombinant target antigen , 2010, Journal of the Neurological Sciences.

[16]  P. Marchiori,et al.  Recurrent neuromyelitis optica in Brazilian patients: clinical, immunological, and neuroimaging characteristics , 2010, Multiple sclerosis.

[17]  Caterina Mainero,et al.  In vivo imaging of cortical pathology in multiple sclerosis using ultra-high field MRI , 2009, Neurology.

[18]  Nikos Evangelou,et al.  A Comparison of 3T and 7T in the Detection of Small Parenchymal Veins Within MS Lesions , 2009, Investigative radiology.

[19]  M. Schlamann,et al.  First Clinical Study on Ultra-High-Field MR Imaging in Patients with Multiple Sclerosis: Comparison of 1.5T and 7T , 2009, American Journal of Neuroradiology.

[20]  Robert A Gross,et al.  Levels of evidence , 2008, Neurology.

[21]  G. Gronseth,et al.  Invited Article: Lost in a jungle of evidence , 2008, Neurology.

[22]  G. Gronseth,et al.  Invited Article: Practice parameters and technology assessments , 2008, Neurology.

[23]  A. Vincent,et al.  Antibody to aquaporin-4 in the long-term course of neuromyelitis optica , 2008, Brain : a journal of neurology.

[24]  Jullie W Pan,et al.  DEMONSTRATING THE PERIVASCULAR DISTRIBUTION OF MS LESIONS IN VIVO WITH 7-TESLA MRI , 2008, Neurology.

[25]  Frédéric Blanc,et al.  Cognitive functions in neuromyelitis optica. , 2008, Archives of neurology.

[26]  B. Weinshenker,et al.  The spectrum of neuromyelitis optica , 2007, The Lancet Neurology.

[27]  F. Paul,et al.  Antibody to Aquaporin 4 in the Diagnosis of Neuromyelitis Optica , 2007, PLoS medicine.

[28]  B. Weinshenker,et al.  A secondary progressive clinical course is uncommon in neuromyelitis optica , 2007, Neurology.

[29]  B. Weinshenker,et al.  Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. , 2006, Archives of neurology.

[30]  B. Weinshenker,et al.  Revised diagnostic criteria for neuromyelitis optica , 2006, Neurology.

[31]  B. Weinshenker,et al.  Brain abnormalities in neuromyelitis optica. , 2006, Archives of neurology.

[32]  Hans Lassmann,et al.  Cortical demyelination and diffuse white matter injury in multiple sclerosis. , 2005, Brain : a journal of neurology.

[33]  A. Bar-Or,et al.  Neuromyelitis optica with hypothalamic involvement , 2005, Multiple sclerosis.

[34]  A. Verkman,et al.  The Journal of Experimental Medicine CORRESPONDENCE , 2005 .

[35]  E. Waubant,et al.  An open label study of the effects of rituximab in neuromyelitis optica , 2005, Neurology.

[36]  M Filippi,et al.  Magnetization transfer and diffusion tensor MRI show gray matter damage in neuromyelitis optica , 2004, Neurology.

[37]  B. Weinshenker,et al.  Neuromyelitis optica , 2003, Neurology.

[38]  Hans Lassmann,et al.  A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. , 2002, Brain : a journal of neurology.

[39]  B. Trapp,et al.  Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions , 2001, Annals of neurology.

[40]  P C O'Brien,et al.  The clinical course of neuromyelitis optica (Devic’s syndrome) , 1999, Neurology.

[41]  R. Mandler,et al.  Devic's neuromyelitis optica: A prospective study of seven patients treated with prednisone and azathioprine , 1998, Neurology.

[42]  G. Comi,et al.  Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. , 1997, Brain : a journal of neurology.

[43]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.